Key Neurodegenerative Diseases

Why This Matters

Neurodegenerative diseases are your window into understanding how specific brain structures and cellular mechanisms translate into observable behavior. When you study Alzheimer's, you're really studying how the hippocampus encodes memory; when you examine Parkinson's, you're seeing what happens when the dopaminergic system fails. These diseases function as natural experiments that reveal the brain's architecture and the consequences when particular systems break down.

For exams, focus on the underlying mechanisms of neurodegeneration: protein aggregation, neurotransmitter depletion, demyelination, and genetic mutations. You'll be asked to connect cellular pathology to behavioral symptoms, compare diseases with overlapping features, and explain why damage to different brain regions produces different deficits. Don't just memorize disease names. Know what each condition teaches us about normal brain function and what goes wrong at the cellular level.

---

Protein Aggregation Disorders

These diseases share a common mechanism: abnormal proteins accumulate in or around neurons, disrupting cellular function and eventually causing cell death. The specific protein involved and where it builds up determine which symptoms emerge.

Alzheimer's Disease

Amyloid-beta plaques (which form between neurons) and neurofibrillary tangles made of hyperphosphorylated tau protein (which form inside neurons) accumulate first in the hippocampus and entorhinal cortex, then spread to the broader cerebral cortex. These deposits disrupt synaptic communication and trigger neuronal death.

• Progressive memory loss begins with recent memories because the hippocampus handles consolidation of new information. As degeneration spreads to cortical areas, older memories, language, and executive function deteriorate too.
• Risk factors include advancing age, the APOE4 gene variant, and poor cardiovascular health. This mix of genetic and lifestyle factors makes Alzheimer's a good example of gene-environment interaction in neurodegeneration.

Lewy Body Dementia

Lewy bodies are abnormal clumps of alpha-synuclein protein that form inside neurons throughout the cortex and brainstem, causing widespread dysfunction.

• Fluctuating cognition and vivid visual hallucinations are the hallmark features that distinguish this from Alzheimer's. These reflect involvement of visual processing areas and brainstem arousal systems.
• Parkinsonism symptoms overlap with Parkinson's disease because both involve alpha-synuclein pathology. This makes differential diagnosis challenging: if dementia appears first, it's typically classified as Lewy body dementia; if motor symptoms come first, it's Parkinson's disease dementia.

Prion Diseases

Misfolded prion proteins (PrPSc) act as a template, forcing normally folded prion proteins to misfold in a chain reaction. This cascading misfolding leads to rapid, fatal neurodegeneration with a characteristic "spongy" appearance of brain tissue.

• Creutzfeldt-Jakob disease (CJD) is the most common human prion disease. It produces rapidly progressive dementia and ataxia over weeks to months rather than years.
• Transmissibility makes prions unique among neurodegenerative causes. Prion diseases can be inherited (familial CJD), arise spontaneously (sporadic CJD), or be acquired through exposure to contaminated tissue (variant CJD from bovine spongiform encephalopathy, or "mad cow disease").

---

Dopaminergic and Basal Ganglia Disorders

These conditions result from degeneration of neurons in the basal ganglia circuit, particularly those producing or responding to dopamine. The basal ganglia regulate movement by balancing excitatory (go) and inhibitory (stop) signals.

Parkinson's Disease

Dopamine-producing neurons in the substantia nigra pars compacta degenerate, reducing dopaminergic input to the striatum. Without enough dopamine, the "go" pathway (direct pathway) is underactive, making it hard to initiate and execute movements.

• Cardinal motor symptoms are resting tremor, rigidity, bradykinesia (slowness of movement), and postural instability. Together, these reflect the basal ganglia's role in producing smooth, voluntary movement.
• Non-motor symptoms include depression, sleep disturbances, and cognitive changes. These reveal that dopamine does more than control movement; it also plays key roles in mood regulation and executive function.

Huntington's Disease

The CAG trinucleotide repeat expansion in the HTT gene causes production of a toxic mutant huntingtin protein. This protein destroys neurons primarily in the caudate nucleus and putamen (collectively, the striatum).

• Chorea (involuntary, jerky, dance-like movements) results from loss of the inhibitory neurons in the striatum that normally suppress unwanted movement. This is the opposite motor pattern from Parkinson's rigidity.
• Autosomal dominant inheritance means a child of an affected parent has a 50% chance of inheriting the mutation. This makes Huntington's a key example of a single-gene neurological disorder. Notably, more CAG repeats correlate with earlier onset (a phenomenon called anticipation).

---

Motor Neuron Diseases

These disorders specifically target motor neurons in the brain, brainstem, or spinal cord, causing progressive weakness and paralysis while often sparing cognition and sensation.

Amyotrophic Lateral Sclerosis (ALS)

Both upper motor neurons (in the motor cortex) and lower motor neurons (in the brainstem and spinal cord) degenerate, causing progressive muscle weakness, atrophy, and eventual paralysis, including of the respiratory muscles.

• Cognition typically remains intact, which demonstrates the selectivity of neurodegeneration. ALS targets motor pathways while largely sparing cortical association areas. (Though it's worth knowing that a subset of ALS patients do develop frontotemporal dementia.)
• Average survival is 3-5 years post-diagnosis, reflecting rapid, relentless progression once symptoms appear. Most cases are sporadic with no clear genetic cause, though about 5-10% are familial.

Spinal Muscular Atrophy (SMA)

Mutations in the SMN1 gene reduce production of survival motor neuron protein, which is essential for motor neuron health. Without it, spinal motor neurons (lower motor neurons only) die, causing progressive muscle weakness.

• Severity varies dramatically by type. Type 1 appears in infancy with severe weakness and breathing difficulty; Type 4 emerges in adulthood with much milder symptoms. The number of copies of a backup gene (SMN2) largely determines severity.
• Gene therapy breakthroughs (such as onasemnogene, which delivers a functional SMN1 gene) make SMA a landmark example of how understanding a disease's genetic mechanism can lead to targeted treatment.

---

Demyelinating and Autoimmune Disorders

Multiple sclerosis demonstrates what happens when the immune system attacks the myelin sheath, disrupting the speed and efficiency of neural transmission throughout the CNS.

Multiple Sclerosis (MS)

The immune system mistakenly targets oligodendrocytes, the glial cells that produce myelin in the CNS. As myelin is stripped from axons in the brain and spinal cord, signal transmission slows or gets blocked entirely.

• Symptoms vary depending on where lesions form. Optic neuritis (visual pathways), limb weakness (motor tracts), numbness or tingling (sensory pathways), and coordination problems (cerebellar connections) can all occur. This variability is why MS is sometimes called "the great imitator."
• Relapsing-remitting MS is the most common form, with episodes of symptoms followed by partial or full recovery. Over time, some patients transition to progressive MS, where disability accumulates steadily. These different courses illustrate how the same underlying mechanism can produce different disease patterns.

---

Frontotemporal and Cerebellar Degeneration

These conditions target specific brain regions outside the classic memory circuits, producing distinctive behavioral and motor syndromes that differ from typical dementia presentations.

Frontotemporal Dementia (FTD)

Selective atrophy of the frontal and temporal lobes causes personality changes, social disinhibition, and language problems rather than the memory loss typical of Alzheimer's. The frontal lobes govern decision-making, impulse control, and social behavior, so their degeneration produces dramatic behavioral shifts.

• Younger onset (typically ages 40-65) and the prominence of behavioral symptoms often lead to initial misdiagnosis as a psychiatric illness like depression or bipolar disorder.
• Language variants include progressive nonfluent aphasia (difficulty producing speech) and semantic dementia (loss of word meaning), demonstrating how focal degeneration of specific temporal lobe regions produces distinct cognitive deficits.

Spinocerebellar Ataxia (SCA)

Progressive degeneration of the cerebellum and spinal cord pathways causes worsening loss of coordination, balance, and fine motor control.

• Multiple genetic subtypes exist, many involving different CAG repeat expansions (similar to Huntington's). This illustrates how the same type of mutation in different genes can produce related but distinct disorders.
• Ataxia (loss of coordinated movement) is the defining feature. It reflects the cerebellum's essential role in motor timing, error correction, and smooth execution of movement sequences.

---

Quick Reference Table

---

Self-Check Questions

1. Which two diseases both involve abnormal protein aggregation but produce different primary symptoms, one affecting memory and the other causing visual hallucinations and motor problems?

2. Parkinson's and Huntington's both affect the basal ganglia. Explain why one produces too little movement while the other produces too much.

3. A patient presents with progressive weakness but intact sensation and cognition. Which two diseases should you consider, and what distinguishes them mechanistically?

4. Compare and contrast Alzheimer's disease and frontotemporal dementia in terms of brain regions affected, typical age of onset, and presenting symptoms.

5. If a question asks you to explain how understanding the genetic basis of a neurodegenerative disease has led to treatment advances, which condition provides the strongest example and why?